Systemic Lupus Erythematosus

Santerus AG is preparing to initiate clinical trials of its blood purification technology in a variety of indications.

New phase 3 trial data reveals Dapirolizumab pegol significantly reduces disease activity and fatigue in systemic lupus erythematosus patients, promising improved treatment outcomes.

A recent study reveals significant variations in biologic use among pregnant patients with autoimmune diseases, highlighting the need for tailored risk-benefit assessments.

A recent meta-analysis confirms belimumab's superior efficacy over placebo in treating systemic lupus erythematosus, potentially informing clinical management strategies.

Patients in the anifrolumab arm also had lower rates of damage accrual.

Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.

The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.

A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.

A new cohort study including over 6 million participants has found an increased likelihood of Behçet disease, alocpecia, bulbous pemphigoid and other disorders post-COVID infection.

Four of 5 participants with follow-up reaching 3 months have achieved SRI-4 disease responses.

A study found that high ultraprocessed food consumption increases the risk of SLE by 56%, with an even higher risk for anti-dsDNA positive SLE at 105%.

The therapy demonstrated superior efficacy in combination with SOC over SOC alone.

Those with limited health literacy had higher disease activity and more SLE damage.

The study highlighted the potential role of shared decision-making in building trust in physicians among patients with SLE.

Results from a Mendelian randomization analysis indicate type 1 diabetes significantly increases the likelihood of autoimmune conditions like rheumatoid arthritis and multiple sclerosis.

Amanda Mixon, PA-C, discusses how rheumatic diseases may first present in skin, ocular or gastric symptoms.

A recent study provides some evidence of the ability to potentially reduce belimumab dose in a subset of patients with SLE.

Karen Costenbader, MD, discusses the 2 post hoc analyses that demonstrated treatment with belimumab reduces flares and increases response rates among patients with early active SLE.

Karen Costenbader, MD, discusses how early intervention with belimumab in patients with lupus significantly reduces disease flares and prevents irreversible organ damage.

Most (94%) anti-nucleocapsid positivity was linked to a self-reported COVID-19 infection within the prior 3 months.

Mohamed Cherry, MD, and Neil Kramer, MD, shed light on a phase 1 trial using CAR-T cell therapy for SLE and its potential implications for lupus treatment.

An analysis of data from more than 5 million people suggests rheumatic and immune-mediated diseases were associated with increased rates of childlessness and elevated risk of adverse pregnancy outcomes.

A groundbreaking phase 1 study using CAR-T cells to treat severe lupus highlights a collaborative effort between the Cellular Therapy Program and rheumatology programs to pioneer innovative patient care.

The Xist ribonucleoprotein (RNP) complex, linked to the XX sex chromosome complement, influences the susceptibility to autoimmunity.